Comparison · NCT04157335-00367d22
Double Blind Benralizumab vs Double Blind Placebo: Percentage of Participants With Surgery and/or Use SCS for CRSwNP
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Double Blind Benralizumab vs Double Blind Placebo: Percentage of Participants With Surgery and/or Use SCS for CRSwNP. Trial comparisons, record NCT04157335-00367d22. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04157335-00367d22
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.187 | 0.131 | 0.26 | wilson | |
| Risk in group 2 | 0.222 | 0.16 | 0.299 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0352 | -0.131 | 0.0605 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.842 | 0.527 | 1.35 | log | |
| Odds ratio, group 1 over group 2 | 0.805 | 0.447 | 1.45 | log | |
| Number needed to treat, for one fewer participant with the outcome on Double Blind Benralizumab than on Double Blind Placebo | 28.4 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Double Blind Benralizumab | 30 mg Benralizumab administered every 4 weeks subcutaneously for the first 3 doses (Weeks 0, 4 and 8) and every 8 weeks (Q8W) thereafter. | 26 | 139 | OG000 |
| Group 2 | Double Blind Placebo | 30 mg Placebo administered every 4 weeks subcutaneously for the first 3 doses (Weeks 0, 4 and 8) and every 8 weeks (Q8W) thereafter. | 30 | 135 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Percentage of Participants With Surgery and/or Use SCS for CRSwNP
- Description
Nasal polyps surgery is defined as any procedure involving instruments resulting in incision and removal of tissue (e.g. polypectomy, endoscopic sinus surgery).~An SCS course can be considered as a new course if the start date is preceded by at least 7 days after the end date of the last SCS course for CRSwNP (i.e. start date of the new course - end date of the last course \> 7)
- Time frame
- Baseline to Week 56
- Population
- Primary full analysis set (All CRSwNP participants with asthma who were randomized and received any IP. N=139 in treatment group and N=135 in placebo).
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)
- NCT number
- NCT04157335
- Phases
- PHASE3
- Conditions
- Nasal Polyposis, Eosinophilic Chronic Rhinosinusitis
- Interventions
- Benralizumab 30 mg, Matched placebo
- Lead sponsor
- AstraZeneca
- Results first posted
- 2026-02-19
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04157335?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04157335-00367d22